Free Papers

Search Title by author or title

Glaucoma treatment in difficult cases with PRESERFLO™ MicroShunt implantation: own results

Free Paper Details

First Author: E.Mrukwa-Kominek POLAND

Co Author(s):    M. Hajduga   M. Dorecka   J. Janiszewska-Salamon   S. Wagner           

Abstract Details


During the treatment of glaucoma, we strive to maintain visual function, and consequently the quality of life. Minimally invasive surgery is promising for glaucoma patients. MicroShunt glaucoma drainage system is intended for reduction of intraocular pressure in eyes of patients with primary open angle glaucoma where IOP remains uncontrollable while on maximum tolerated medical therapy and/or where glaucoma progression warrants surgery. The aim of the study is to assess the efficacy and safety of implanting a PRESERFLO ™ MicroShunt implant (Santen, Japan) in patients with glaucoma in whom previous treatments have not resulted in an adequate reduction of intraocular pressure (IOP)


1University Clinical Center Professor K. Gibinski of the Medical University of Silesia in Katowice, Department of Ophthalmology, Poland 2Department of Ophthalmology, School of Medicine in Katowice, Medical University of Silesia, Poland


From October 2019 to February 2020 14 implantations (12 patients) of PRESERFLO ™ MicroShunt were performed. Patients with glaucoma, whose previous treatment methods were not sufficient to achieve the target IOP, were qualified for the procedure. Before the surgery 14 days steroid prophylaxis was recommended. Surgery: subconjunctival anesthesia, an incision was made below the limbus, implant was placed with a short arm under the Tenon's capsule, and a longer arm in the anterior chamber of the eye. Before and after the operation there were analyzed: visual acuity, visual field, IOP, number of active substances in the drops and postoperative complications


The analyzed group of 12 patients consisted of 7 women and 5 men, age 33-79. Before that op 8 patients underwent glaucoma manual surgery, 4 patient laser surgery. Visual acuity before, one, 14, 30 and 90 days post op remained level respectively 0.70; 0.50, 0.78, 0.68, 0.70 . IOP in the same observation period was 26.13, 13.5, 14.0, 15.6, 15.5 respectively. A significant reduction in IOP compared to IOP before surgery(p<0.05). Decreased number of active ingredients in the applied drops of 0 to a maximum of 1.5. Adverse reactions: one patient transient shallow anterior chamber and slight uveal elevation


The use of the PRESERFLO ™ implant is an effective and safe method of reducing intraocular pressure, also in difficult glaucoma patients. During the observation period, a reduction in the number of active substances in eye drops was significant. In addition, the procedure can be performed both after ineffective trabeculectomy or laser procedures, without excluding these operations in the future.

Financial Disclosure:


Back to Free Papers listing